| Anthony Matteo Simone, MD | |
|
3475 Torrance Blvd Ste A, Torrance, CA 90503-5800 | |
| (310) 370-3568 | |
| Not Available |
| Full Name | Anthony Matteo Simone |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 3475 Torrance Blvd Ste A, Torrance, California |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194188581 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | A155785 (California) | Secondary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | A155785 (California) | Primary |
| Entity Name | Southern California Permanente Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770515280 PECOS PAC ID: 6002729175 Enrollment ID: O20031110000678 |
News Archive
Today in Canberra, Tony Abbott has let slip a historic opportunity for health reform. Today the state and federal health ministers met and had Professor John Dwyer and some of the finest minds in health give them health reform proposals.
For years, science has generally considered the phosphorylation of proteins - the insertion of a phosphorous group into a protein that turns it on or off - as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death. Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism - called sulfenylation - that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer.
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
My sister's cancer sent me into the medical literature with an insatiable hunger for information. It's this search for answers and 20 years of experience caring for women many of whom bore physical or emotional scars acquired in the aftermath of suspicious or inconclusive mammograms that led me to decide that I could no longer endorse the tests as routine screening measures for me or any other woman
Family carers need to be supported throughout the whole illness of their loved ones as they witness and share much of the experience of the dying person, according to research published on bmj.com today.
› Verified 6 days ago
| Entity Name | Providence Medical Institute |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417915760 PECOS PAC ID: 5991609737 Enrollment ID: O20031121000910 |
News Archive
Today in Canberra, Tony Abbott has let slip a historic opportunity for health reform. Today the state and federal health ministers met and had Professor John Dwyer and some of the finest minds in health give them health reform proposals.
For years, science has generally considered the phosphorylation of proteins - the insertion of a phosphorous group into a protein that turns it on or off - as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death. Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism - called sulfenylation - that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer.
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
My sister's cancer sent me into the medical literature with an insatiable hunger for information. It's this search for answers and 20 years of experience caring for women many of whom bore physical or emotional scars acquired in the aftermath of suspicious or inconclusive mammograms that led me to decide that I could no longer endorse the tests as routine screening measures for me or any other woman
Family carers need to be supported throughout the whole illness of their loved ones as they witness and share much of the experience of the dying person, according to research published on bmj.com today.
› Verified 6 days ago
| Entity Name | Southern California Hospitalist Network Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790880458 PECOS PAC ID: 8921990110 Enrollment ID: O20040324001749 |
News Archive
Today in Canberra, Tony Abbott has let slip a historic opportunity for health reform. Today the state and federal health ministers met and had Professor John Dwyer and some of the finest minds in health give them health reform proposals.
For years, science has generally considered the phosphorylation of proteins - the insertion of a phosphorous group into a protein that turns it on or off - as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death. Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism - called sulfenylation - that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer.
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
My sister's cancer sent me into the medical literature with an insatiable hunger for information. It's this search for answers and 20 years of experience caring for women many of whom bore physical or emotional scars acquired in the aftermath of suspicious or inconclusive mammograms that led me to decide that I could no longer endorse the tests as routine screening measures for me or any other woman
Family carers need to be supported throughout the whole illness of their loved ones as they witness and share much of the experience of the dying person, according to research published on bmj.com today.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Anthony Matteo Simone, MD 5767 W Century Blvd Ste 400, Los Angeles, CA 90045-5631 Ph: () - | Anthony Matteo Simone, MD 3475 Torrance Blvd Ste A, Torrance, CA 90503-5800 Ph: (310) 370-3568 |
News Archive
Today in Canberra, Tony Abbott has let slip a historic opportunity for health reform. Today the state and federal health ministers met and had Professor John Dwyer and some of the finest minds in health give them health reform proposals.
For years, science has generally considered the phosphorylation of proteins - the insertion of a phosphorous group into a protein that turns it on or off - as perhaps the factor regulating a range of cellular processes from cell metabolism to programmed cell death. Now, scientists from the Florida campus of The Scripps Research Institute have identified the importance of a novel protein-regulating mechanism - called sulfenylation - that is similar to phosphorylation and may, in fact, open up opportunities to develop new types of drugs for diseases such as cancer.
iCo Therapeutics Inc. today announced that the company has entered into a research collaboration agreement with JDRF, the worldwide leader for research to cure, treat, and prevent type 1 diabetes (T1D), to support the previously announced Phase 2 investigator sponsored clinical trial investigating iCo-007 in Diabetic Macular Edema.
My sister's cancer sent me into the medical literature with an insatiable hunger for information. It's this search for answers and 20 years of experience caring for women many of whom bore physical or emotional scars acquired in the aftermath of suspicious or inconclusive mammograms that led me to decide that I could no longer endorse the tests as routine screening measures for me or any other woman
Family carers need to be supported throughout the whole illness of their loved ones as they witness and share much of the experience of the dying person, according to research published on bmj.com today.
› Verified 6 days ago
Deborah Chon, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3445 Pacific Coast Hwy Ste 100, Torrance, CA 90505 Phone: 310-542-6333 | |
Erika Joyce Kalash, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3565 Del Amo Blvd, Torrance, CA 90503 Phone: 310-214-0811 | |
Hosayn Khaleeli, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2245 Sepulveda Blvd, Torrance, CA 90501 Phone: 310-320-3204 Fax: 310-320-0919 | |
Mr. Anthony C Dike, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 20280 S Vermont Ave Ste 215, Torrance, CA 90502 Phone: 323-434-4626 Fax: 310-693-8082 | |
Paul J Brown, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3333 Skypark Dr, Torrance, CA 90505 Phone: 310-517-9006 | |
Dr. Philip W Chung, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2841 Lomita Blvd 215, Torrance, CA 90505 Phone: 310-379-2860 Fax: 310-325-1144 | |
Dr. Diane Jennifer Prager, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 3445 Pacific Coast Hwy Ste 300, Torrance, CA 90505 Phone: 310-325-8252 |